Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Medical University of Vienna
The objectives of this study are to evaluate the effectivity and the safety of bortezomib in patients with disseminated MALT lymphoma or at relapse following HP-eradication, or chemotherapy or radiation.
It is a phase II prospective single arm study with a target sample of 16 patients. 1.5mg/m2 Bortezomib is given intravenously on day 1,4,8,11 every three week, for a maximum of 8cycles.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
patients with histologically confirmed MALT lymphoma with measurable disease (stage I-IV)
with first or greater relapse after HP-eradication, radiation or chemotherapy ,
age \> 18 years
must be able to tolerate therapy and have adequate cardiac, renal and hepatic function
ECOG status of \<\_ 2
must be capable of understanding the purpose of the study and given written informed consent